FDA is investigating postmarketing reports of lymphoma and skin cancer in children and adults treated with Elidel ( Pimecrolimus ), but the causal relationship has not been clearly established.
FDA is continuing to analyze these reports to determine whether the occurrence of these adverse events affects the risk/benefit assessment of Elidel therapy.
Elidel is approved for the treatment of atopic dermatits in adults and children ages two years and older. This topical cream should be applied twice-daily. Elidel is the first non-steroid prescription for mild to moderate atopic dermatitis for use in children and adults and is one of the first new treatments since topical corticosteroids were introduced almost 50 years ago.